Skip to content

Study · In vitro (cells) · 2025

11 results

Exploring the therapeutic potential of MOTS-c in age-related macular degeneration: from cellular responses to patient-derived cybrids.

Mohtashami Z, Schneider K, Azimi R, Atilano S, Chwa M, Kenney MC, Singh MK

Human cell17 Feb 2025Cited by 4 (Europe PMC)

PMID39961901 (opens in a new tab)DOI10.1007/s13577-025-01188-w (opens in a new tab)PepBankPUB-39961901
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In ARPE19 cells, the response to MOTS‑c differed between wild-type and differentiated cells.

    In plain wordsIn lab cells, MOTS‑c had different effects in wild-type and differentiated retinal cells.

    Peptide
    MOTS-c
    Outcome
    MixedResponse to MOTS-c, wild-type versus differentiated ARPE19 cells
    Study

    n: not reported in source

    wild-type and differentiated ARPE19 cells
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, we show that there are differences in effects between wild-type (wt-) and differentiated ARPE19 cells (diff-ARPE19), implying that the cellular differentiation status may influence how cells respond to MOTS-c.
  2. 02LabIn vitro (cells)Mechanism

    In differentiated ARPE19 cells, MOTS‑c had dose-dependent effects on apoptosis, inflammation and mitochondrial biogenesis.

    In plain wordsIn lab cells, the effects of MOTS‑c on cell death, inflammation and mitochondria depended on the dose.

    Peptide
    MOTS-c
    Outcome
    MixedDose-dependent effects on apoptosis, inflammation and mitochondrial biogenesis
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c has dose-dependent effects on apoptosis, inflammation, and mitochondrial biogenesis in diff-ARPE19 cells.
  3. 03LabIn vitro (cells)Mechanism

    In differentiated ARPE19 cells, the lower dose of MOTS‑c (500 nM) had more significant effects than 5 µM.

    In plain wordsIn lab cells, a lower dose of MOTS‑c had stronger effects than a higher dose.

    Peptide
    MOTS-c
    Outcome
    MixedEffect of 500 nM versus 5 µM MOTS-c
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Neuroprotection · Eye
    Studied dose
    500 nM and 5 µMAs given in this study.

    Measurements

    Dose
    500 nM
    lower dose
    Dose
    5 µM
    higher dose

    Source sentences

    Summary
    Lower doses (500 nM) have more significant impacts than 5 µM concentrations.
  4. 04LabIn vitro (cells)Efficacy outcome

    In differentiated ARPE19 cells, a lower dose of MOTS‑c reduced the negative effect of hypoxia on cell survival.

    In plain wordsIn lab cells, a lower dose of MOTS‑c reduced the harm of low oxygen on cell survival.

    Peptide
    MOTS-c
    Outcome
    IncreaseCell survival under hypoxia
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Neuroprotection · Eye
    Studied dose
    500 nMAs given in this study.

    Source sentences

    Summary
    In diff-ARPE19 cells, a lower dose of MOTS-c can reduce the negative impact of hypoxia on cellular survival and gene expression, including apoptosis (CASP3, CASP9), mitochondrial biogenesis (TFAM, PGC-1α), and metabolic sensor (AMPK).
    1 context sentence
    Summary · context
    Lower doses (500 nM) have more significant impacts than 5 µM concentrations.
  5. 05LabIn vitro (cells)Mechanism

    In differentiated ARPE19 cells, a lower dose of MOTS‑c reduced the negative effect of hypoxia on expression of apoptosis genes CASP3 and CASP9.

    In plain wordsIn lab cells, a lower dose of MOTS‑c reduced the effect of low oxygen on cell-death genes.

    Peptide
    MOTS-c
    Outcome
    Not applicableApoptosis gene expression (CASP3, CASP9) under hypoxia
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Neuroprotection · Eye
    Studied dose
    500 nMAs given in this study.

    Source sentences

    Summary
    In diff-ARPE19 cells, a lower dose of MOTS-c can reduce the negative impact of hypoxia on cellular survival and gene expression, including apoptosis (CASP3, CASP9), mitochondrial biogenesis (TFAM, PGC-1α), and metabolic sensor (AMPK).
    1 context sentence
    Summary · context
    Lower doses (500 nM) have more significant impacts than 5 µM concentrations.
  6. 06LabIn vitro (cells)Mechanism

    In differentiated ARPE19 cells, a lower dose of MOTS‑c reduced the negative effect of hypoxia on TFAM and PGC-1α expression.

    In plain wordsIn lab cells, a lower dose of MOTS‑c reduced the effect of low oxygen on genes for new mitochondria.

    Peptide
    MOTS-c
    Outcome
    Not applicableMitochondrial biogenesis gene expression (TFAM, PGC-1α) under hypoxia
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Mitochondrial function · Eye
    Studied dose
    500 nMAs given in this study.

    Source sentences

    Summary
    In diff-ARPE19 cells, a lower dose of MOTS-c can reduce the negative impact of hypoxia on cellular survival and gene expression, including apoptosis (CASP3, CASP9), mitochondrial biogenesis (TFAM, PGC-1α), and metabolic sensor (AMPK).
    1 context sentence
    Summary · context
    Lower doses (500 nM) have more significant impacts than 5 µM concentrations.
  7. 07LabIn vitro (cells)Mechanism

    In differentiated ARPE19 cells, a lower dose of MOTS‑c reduced the negative effect of hypoxia on expression of the metabolic sensor AMPK.

    In plain wordsIn lab cells, a lower dose of MOTS‑c reduced the effect of low oxygen on an energy-sensing gene.

    Peptide
    MOTS-c
    Outcome
    Not applicableMetabolic sensor AMPK expression under hypoxia
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Mitochondrial function · Eye
    Studied dose
    500 nMAs given in this study.

    Source sentences

    Summary
    In diff-ARPE19 cells, a lower dose of MOTS-c can reduce the negative impact of hypoxia on cellular survival and gene expression, including apoptosis (CASP3, CASP9), mitochondrial biogenesis (TFAM, PGC-1α), and metabolic sensor (AMPK).
    1 context sentence
    Summary · context
    Lower doses (500 nM) have more significant impacts than 5 µM concentrations.
  8. 08LabIn vitro (cells)Mechanism

    In differentiated ARPE19 cells, MOTS‑c had no significant effect on ROS levels at either dose.

    In plain wordsIn lab cells, MOTS‑c did not significantly change reactive oxygen levels at any dose.

    Peptide
    MOTS-c
    Outcome
    No significant changeROS levels
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Mitochondrial function · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, it had no significant effect on ROS levels or NRF1 expression, regardless of MOTS-c dose.
  9. 09LabIn vitro (cells)Mechanism

    In differentiated ARPE19 cells, MOTS‑c had no significant effect on NRF1 expression at either dose.

    In plain wordsIn lab cells, MOTS‑c did not significantly change NRF1 gene expression at any dose.

    Peptide
    MOTS-c
    Outcome
    No significant changeNRF1 expression
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Outcome group
    Mitochondrial function · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, it had no significant effect on ROS levels or NRF1 expression, regardless of MOTS-c dose.
  10. 10LabIn vitro (cells)Efficacy outcome

    In differentiated ARPE19 cells under chemical hypoxia, MOTS‑c before and after treatment gave no extra benefit compared with MOTS‑c alone.

    In plain wordsIn lab cells, giving MOTS‑c both before and after low-oxygen exposure gave no extra benefit compared with MOTS‑c alone.

    Peptide
    MOTS-c
    Outcome
    No significant changeMOTS-c before and after hypoxic exposure versus MOTS-c alone
    Study

    n: not reported in source

    differentiated ARPE19 cells
    Comparator
    MOTS-c treatment alone
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exposing diff-ARPE19 cells to varied MOTS-c dosages before and after therapy in a chemically induced hypoxic environment yields no extra benefits as compared to MOTS-c treatment alone.
  11. 11LabIn vitro (cells)Mechanism

    In cybrids from patients with AMD, MOTS‑c changed expression of apoptosis, mitochondrial biogenesis and antioxidant genes differently than in age-matched control cybrids.

    In plain wordsIn patient-derived lab cells with AMD, MOTS‑c changed gene activity differently than in cells from matched controls.

    Peptide
    MOTS-c
    Outcome
    MixedGene expression in AMD patient versus control cybrids
    Study

    n: not reported in source

    patient-derived cybrids
    Comparator
    Age-matched control cybrids
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c had different effects on the expression of genes linked with apoptosis, mitochondrial biogenesis, and antioxidant activity in AMD patients versus age-matched control cybrids.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 08:19 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.